Precision Medicine in the COVID-19 Crisis
While patients are at home, continue cancer care with select diagnostic tests
COVID-19 has caused significant disruption in the care of cancer patients. Follow-up visits are postponed, new biopsies are on hold and cancer testing, in many cases, has not been ordered. The National Cancer Institute (NCI) recommends cancer patients to stay at home as much as possible, boosting the volume telemedicine visits between oncology providers and their patients. Therefore, NeoGenomics is providing a list of cancer tests that can be performed using a simple blood draw or pre-existing biopsy tissue to comply with NCI guidance.
All of NeoGenomics’ main laboratory facilities remain open and will continue to provide testing services for your cancer patients. We understand how critical it is to maintain optimal patient care and we are committed to deliver you quality testing, excellent service and other laboratory offerings during this challenging time.
Order Testing on Archival Tissue
Most tumor driver gene mutations are generally stable and once they appear, will remain through cancer progression in the absence of negative selection1,2 such as the one imposed by an effective therapy. Studies have shown that most driver mutations detected in primary tumors, including PIK3CA mutations, are also detected in advanced or metastatic lesions3,4.
To order testing using a previous biopsy please FAX in the designated test requisition form and pathology report to NeoGenomics’ Client Services team and we will retrieve the specimen listed on the pathology report for testing. For PIK3CA Mutation CDx orders please FAX in the custom Test Form to enroll patients in the PIK3CA Mutation CDx Testing Program that provides appropriate patients one free PIK3CA Mutation CDx test.
Tests that can be performed on a minimally invasive, peripheral blood sample
NeoLAB® Liquid Biopsy testing and COMPASS® for Hematologic Malignancies
Please download our comprehensive solid tumor and heme test menu using a peripheral blood sample.
NeoGenomics is proud to announce the availability of COVID-19 or SARS-CoV-2 Detection by PCR Testing. If you are interested in referring COVID-19 cases to NeoGenomics, please email NeoGenomics’ special COVID-19 Hotline. The list price for the SARS-CoV-2 Detection by PCR is $100.
For any questions please contact our NeoGenomics’ Client Services at 866.776.5907, option 3 or email Client.Services@neogenomics.com.
- Vogelstein et al., Science 29 Mar 2013:Vol. 339, Issue 6127, pp. 1546-1558. PMID 23539594
- Martincorena et al., Cell .2017 Nov 16;171(5):1029-1041.e21.PMID: 29056346
- Arthur et al. Breast Cancer Res Treat. 2014 Aug;147(1):211-9. PMID: 25104442
- Fumagalli et al., Ann Oncol. 2016 Oct;27(10):1860-6. PMID: 27672107
*InVisionFirst is a UK, EU and US registered trade mark of Inivata Limited
Healthcare Community Unite
NeoGenomics unites with organizations from the healthcare community to form COVID-19 Testing Industry Consortium.
COVID Testing Industry Consortium
COVID-19: Preparing for the Fall
Donate your plasma
Antibodies in your COVID-19 plasma could help others fight the disease. To register to donate plasma, please click the link below.